Skip to main content

Ikena Oncology, Inc. (IKNA)

NASDAQ: IKNA · Delayed Price · USD
12.81 -0.18 (-1.39%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap537.08M
Revenue (ttm)9.92M
Net Income (ttm)n/a
Shares Out35.86M
EPS (ttm)-4.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,859
Open13.01
Previous Close12.99
Day's Range12.62 - 13.12
52-Week Range9.63 - 37.61
Betan/a
Analystsn/a
Price Target27.00 (+110.8%)
Est. Earnings DateNov 11, 2021

About IKNA

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degradi...

IndustryBiotechnology
IPO DateMar 26, 2021
Employees50
Stock ExchangeNASDAQ
Ticker SymbolIKNA
Full Company Profile

Financial Performance

In 2020, Ikena Oncology's revenue was $9.19 million, a decrease of -33.15% compared to the previous year's $13.75 million. Losses were -$44.26 million, 163.2% more than in 2019.

Financial Statements

News

Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced...

3 weeks ago - GlobeNewsWire

Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and s...

2 months ago - GlobeNewsWire

Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, ...

3 months ago - Business Wire

Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, ...

4 months ago - Business Wire

Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

5 months ago - Business Wire

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying...

Other symbols:ATNFEVLO
5 months ago - Benzinga

Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purch...

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

5 months ago - Business Wire

Ikena Oncology Announces Pricing of Initial Public Offering

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer...

5 months ago - Business Wire

Phase 1 cancer biotech Ikena Oncology files for a $100 million IPO

Ikena Oncology, a phase 1 oncology biotech developing small molecule inhibitor therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

Ikena Oncology IPO Registration Document (S-1)

Ikena Oncology, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC